ArticleThe Journal of clinical endocrinology and metabolism2025
Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Postprandial Glucose Spikes in Free-Living Adults With Normoglycaemia Are Associated With Modifiable Dietary and Temporal Factors: A Real-World CGM Study.Diabetes, obesity & metabolism · 2026Article
- Continuous glucose monitoring in paediatric residents with normal glucose metabolism: correlations to 24-hour duty schedule.Journal of diabetes and metabolic disorders · 2026Article
- Continuous glucose monitoring as a tool in early-stage type 1 diabetes.Diabetologia · 2026Review
- Article
- Hypoglycemia Occurrence and Risk Factors in Insulin Independent Patients After Total Pancreatectomy With Islet Autotransplantation.Clinical transplantation · 2026Article
- Canonical and Alternative Pathways (Insulin and Exercise) of GLUT4 Synthesis, Signaling, Intracellular Clustering, and Recruitment to the Plasma Membrane.International journal of molecular sciences · 2026Review
- Summarizing data from continuous glucose monitors using the cgmstats package.medRxiv : the preprint server for health sciences · 2026Article
- Differences in Continuous Glucose Monitoring Metrics Between Prediabetes and Normoglycemia: A Systematic Review and Meta-Analysis.Journal of diabetes science and technology · 2026Review
- Association of Insulin Resistance and Insulin Secretion Indices and Glucose Metrics From Continuous Glucose Monitoring in People With Obesity.Diabetes care · 2026Article
- Continuous Glucose Monitoring Metrics in Asians Without Diabetes: Differentiating Prediabetes From Normoglycemia.Journal of diabetes science and technology · 2025Article
- Associations of diet composition and quality with continuous glucose monitor-derived glycemic metrics in a community-based cohort.The American journal of clinical nutrition · 2025Article
- Short-term pre-meal whey protein microgel supplementation reduces postprandial glycemia and appetite in adults with overweight: An open-label randomised controlled trial.Obesity pillars · 2025Article
- Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
contextContinuous glucose monitor (CGM) companies are beginning to market these sensors to populations without diabetes, but the range of CGM values clinicians should expect to see for this population is unclear because there have been no large studies reporting these ranges.
objectiveThis work aimed to report the physiological range of CGM time in range values observed across glycemic status, including individuals without diabetes, to serve as a reference for clinicians.
methodsThe Framingham Heart Study, a prospective cohort study, was conducted among community-dwelling adults with normoglycemia (n = 560), prediabetes (n = 463), and diabetes (n = 152). We conducted a cross-sectional investigation in participants who wore a Dexcom G6 Pro CGM (in blinded mode) for 7 or more complete days. Main outcome measures included CGM metrics including mean glucose and time spent in glucose ranges.
resultsNormoglycemic participants (mean age 58.5 years, 64.5% women, 93.3% non-Hispanic White) spent 87.0% time in the 70 to 140 mg/dL CGM range, and, on average, more than 15 minutes/day (1.2% time) at more than 180 mg/dL. Furthermore, normoglycemic participants spent approximately 3 hours/day (12.1% time) with CGM glucose at more than 140 mg/dL. On average, participants with prediabetes and diabetes spent 77.1% and 46.2% of time in the 70 to 140 mg/dL range, respectively.
conclusionOur results contribute to the understanding of the physiological CGM range in more than 1000 participants without diabetes. These results are also important for clinicians to reference as CGM sensors become more widely accessible to people without known diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.